» Articles » PMID: 24883085

The Difficulties in Cancer Treatment

Overview
Specialty Oncology
Date 2014 Jun 3
PMID 24883085
Citations 98
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer is clearly the most deadly disease in the developed world as one in three people develop cancer during their lifetime. The cure for cancer is like the Holy Grail since most of the existing treatments are not effective enough to provide full protection from this disease. In recent years the burgeoning of sophisticated genomic, proteomic and bioinformatics techniques has made it possible for us to get a glimpse of the intricate interplay of numerous cellular genes and regulatory genetic elements that are responsible for the manifestation of cancerous phenotypes. With the use of modern genomic technologies we are now beginning to understand the enormous complexity of cancer. However there are few success stories as far as the treatment of cancer is concerned. For instance the treatments of leukemia and lymphoma have been established and proved to be satisfactory. Despite occasional successes the treatment for most cancers is still a long way from reality. In this editorial, we have addressed several reasons for the difficulties in cancer treatment.

Citing Articles

Differentiating Induced Pluripotent Stem Cells into Natural Killer Cells for Adoptive Cell Immunotherapies-Comparative Characterization of Current Protocols.

Budagova T, Efremova A, Usman N, Mokrousova D, Goldshtein D Int J Mol Sci. 2025; 26(3).

PMID: 39940874 PMC: 11816922. DOI: 10.3390/ijms26031107.


Role of bacteria in cancers and their therapeutic potential: Review of current knowledge.

Wawrety W, Kedziora A Iran J Basic Med Sci. 2025; 28(3):273-282.

PMID: 39906620 PMC: 11790194. DOI: 10.22038/ijbms.2024.77667.16798.


Characterizing the pan-cancer role of exosomal miRNAs in metastasis across cancers.

Agrawal P, Olgun G, Singh A, Gopalan V, Hannenhalli S Comput Struct Biotechnol J. 2025; 27:252-264.

PMID: 39866667 PMC: 11763893. DOI: 10.1016/j.csbj.2024.12.025.


Anticancer benzimidazole derivatives as inhibitors of epigenetic targets: a review article.

Wagih N, Abdel-Rahman I, El-Koussi N, Abuo-Rahma G RSC Adv. 2025; 15(2):966-1010.

PMID: 39807197 PMC: 11726184. DOI: 10.1039/d4ra05014b.


Targeting Cancer: Microenvironment and Immunotherapy Innovations.

Padzinska-Pruszynska I, Taciak B, Kiraga L, Smolarska A, Gorczak M, Kucharzewska P Int J Mol Sci. 2025; 25(24.

PMID: 39769334 PMC: 11679359. DOI: 10.3390/ijms252413569.


References
1.
Copland M, Jorgensen H, Holyoake T . Evolving molecular therapy for chronic myeloid leukaemia--are we on target?. Hematology. 2005; 10(5):349-59. DOI: 10.1080/10245330500234195. View

2.
Raaijmakers M, de Grouw E, Heuver L, van der Reijden B, Jansen J, Scheper R . Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia. Clin Cancer Res. 2005; 11(6):2436-44. DOI: 10.1158/1078-0432.CCR-04-0212. View

3.
Laird P, Fazeli A, Dickinson S, Jung W, Li E, Weinberg R . Suppression of intestinal neoplasia by DNA hypomethylation. Cell. 1995; 81(2):197-205. DOI: 10.1016/0092-8674(95)90329-1. View

4.
Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

5.
Chen W, Cooper T, Zahnow C, Overholtzer M, Zhao Z, Ladanyi M . Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell. 2004; 6(4):387-98. DOI: 10.1016/j.ccr.2004.08.030. View